CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病

Abstract

Recommended Article

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) The Year in Cardiovascular Medicine 2020: Coronary Prevention: Looking back on the Year in Cardiovascular Medicine for 2020 in the field of coronary prevention is Professor Ramon Estruch, Dr Luis Ruilope, and Professor Francesco Cosentino. Mark Nicholls meets them Association of Coronary Artery Calcium With Long-term, Cause-Specific Mortality Among Young Adults Association Between Depressive Symptoms and Incident Cardiovascular Diseases Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data The Science Underlying COVID-19: Implications for the Cardiovascular System

Guideline31 August 2019

JOURNAL:Eur Heart J. Article Link

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

F Mach, C Baigent, ESC Scientific Document Group et al. Keywords: Guidelines; dyslipidaemias; cholesterol; triglycerides; low-density lipoproteins; high-density lipoproteins; apolipoprotein B; lipoprotein(a); lipoprotein remnants; total cardiovascular risk; treatment (lifestyle); treatment (drugs); treatment (adherence); very low-density lipoproteins; familial hypercholesterolaemia

FULL TEXT PDF